Just one final thought before I hit the sack, with regards to your comment that:"it is all resting on the science at the moment".

I don't disagree, but the scientific data related to the BETonMACE cognition data is already known at this point. It simply hasn't been announced to the market yet.  Its like after an election, where all the ballots have been counted and the results are fixed, but havne't yet been announced.  

The company has already put out a PR stating right up front that Apabetalone improves cognition in CVD patients with diabetes.  All we're waitng to find out at this point is how much improvement, and how the market will react to the news.

My read of the chart has me expecting a very positive reaction.